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Abstract
Microparticles (MPs) play a vital role in cell communication by facilitating the horizontal transfer of cargo between cells.
Recently, we described a novel ‘‘non-genetic’’ mechanism for the acquisition of multidrug resistance (MDR) in cancer cells
by intercellular transfer of functional P-gp, via MPs. MDR is caused by the overexpression of the efflux transporters P-
glycoprotein (P-gp) and Multidrug Resistance-Associated Protein 1 (MRP1). These transporters efflux anticancer drugs from
resistant cancer cells and maintain sublethal intracellular drug concentrations. By conducting MP transfer experiments, we
show that MPs derived from DX breast cancer cells selectively transfer P-gp to malignant MCF-7 breast cells only, in contrast
to VLB100 leukaemic cell-derived MPs that transfer P-gp and MRP1 to both malignant and non-malignant cells. The observed
transfer selectivity is not the result of membrane restrictions for intercellular exchange, limitations in MP binding to
recipient cells or the differential expression of the cytoskeletal protein, Ezrin. CD44 (isoform 10) was found to be selectively
present on the breast cancer-derived MPs and not on leukaemic MPs and may contribute to the observed selective transfer
of P-gp to malignant breast cells observed. Using the MCF-7 murine tumour xenograft model we demonstrated the stable
transfer of P-gp by MPs in vivo, which was found to localize to the tumour core as early as 24 hours post MP exposure and
to remain stable for at least 2 weeks. These findings demonstrate a remarkable capacity by MPs to disseminate a stable
resistant trait in the absence of any selective pressure.
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Introduction
Cell-cell communication is vital for the co-ordination of
physiological processes and for the regulation of the organism’s
phenotype. Cells’ communicate via the release of specific
molecules i.e. in autocrine signalling, endocrine signalling or
across gap-junctions. Cells also communicate by direct cell-cell
contact [1] or via supramolecular mechanisms involving cellular
membrane blebs/fragments including; membrane vesicles or
microparticles (MPs) [2,3], exosomes [4,5], apoptotic bodies [6],
tunnelling nanotubes [7,8] and cytoneme or filopodial bridges [9].
Membrane vesicle signaling, although not as complex as that
observed with soluble mediators, has been shown to contribute to
many distinct processes. These include; microglial-astrocyte
interactions [10], coagulation, inflammation [11,12], cell metab-
olism [13,14], HIV-1 [15], cancer progression [16,17] and drug
resistance [2]. The horizontal transfer of mRNAs and miRNAs by
tumour derived membrane vesicles have been shown to contribute
to conferring numerous malignant traits [3,18].
Microparticles (MPs) are small (0.1–1 mm in diameter) mem-
brane vesicles formed by the direct budding of the plasma
membrane, and which display phosphatidylserine (PS) on their
surface [19]. MPs are released from various cell types following a
breakdown of membrane asymmetry and cytoskeletal remodeling
during the ubiquitous cellular phenomenon of membrane budding
[20]. MPs can be distinguished from exosomes by size (exosomes
typically ranging 40–100 nm in diameter), as well as by origin
[21]. MPs carry a wide range of bioactive material on their surface
and serve as carriers of surface antigens, adhesion molecules as
well as cellular and nuclear constituents from their originating cells
[2,15,22]. The presence of cell adhesion molecules on MPs confers
a capacity for target cell binding and cell-cell interactions [15].
In 2009, we first described a novel MP mediated ‘‘non-genetic’’
mechanism for the acquisition of multidrug resistance (MDR) in
cancer cells, whereby MPs serve as vectors in the intercellular
transfer of functional P-gp from MDR donor cells to drug sensitive
recipient cells (1). Furthermore, we have since demonstrated that
MPs play a more deleterious role in cancer cell biology by
incorporating and transferring a variety of nucleic acid species [18]
and by ‘‘re-templating’’ the transcriptional landscape of recipient
cells to ensure the acquisition of deleterious cancer traits [23]. This
phenomenon appears further regulated by a process of selective
MP packaging and transfer of nucleic acid species to recipient cells
[18]. Herein, we expand on these earlier findings to demonstrate
that MP transfer of P-gp is a ‘‘tissue selective’’ process dependent
on the donor MP type. We demonstrate that the cell adhesion
molecule CD44 (isoform 10) is exclusively present on the breast
cancer-derived MPs relative to the leukaemic cell-derived MPs.
We further propose that the involvement of MP surface molecules
and FERM domain proteins could be responsible for the observed
transfer selectivity. We also demonstrate that drug resistant MPs
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can confer the acquired MDR phenotype to recipient cells in vivo,
resulting in the transfer of P-gp within the tumour core as early as
24 hours post MP exposure. This acquired phenotype was stable




In this study, three different types of human malignant cell lines
overexpressing P-gp or MRP1 and three human non-malignant
primary cells were used. CCRF-CEM (CEM) [24] is a drug-
sensitive human acute lymphoblastic leukaemia cell line, of which
VLB100 [25] (overexpressing P-gp) and E1000 [26] (overexpressing
MRP1) are its MDR variants. MCF-7 [27] is a drug sensitive
human breast adenocarcinoma cell line, of which MCF-7/DX
(DX) [28] (overexpressing P-gp) is its MDR variant. MCF-7/P-
gp/EGFP is a MCF-7 cell stably transfected with a P-gp enhanced
green fluorescent fusion tagged protein [29]. The leukaemic cell
lines were a kind gift from Prof Ross Davey (Royal North Shore
Hospital, The University of Sydney, NSW, Australia) and the
breast cancer cell lines were gifts from Dr Rosanna Supino (Istituto
Nazionale per lo Studio e la Cura dei Tumouri, Milan, Italy) and
Dr Suzanne M. Cutts (La Trobe University, Victoria, Australia).
Both drug sensitive cell lines and the MDR variants have been
validated as an appropriate model for the study of P-gp- or MRP1-
mediated MDR in vitro [2,30,31]. All cancer cell lines were
cultured in RPMI-1640 (Life Technologies, VIC, Australia)
containing 10% FCS (Life Technologies) and maintained under
humidified conditions at 37uC in an atmosphere of 5% CO2.
Human mammary basal epithelial cells (MBE) obtained from
the mammary tissue of a healthy female, were purchased from
Zenbio Inc. (NC, USA) and cultured in DMEM/F12 media. The
human osteoblasts–femural (HO-f) were cultured in Osteoblast
medium and the Human Urothelial cells (HUC) cultured in
Urothelial cell medium were obtained from ScienceCell Research
Laboratories (CA, USA). These cells were maintained under
humidified conditions at 37uC in an atmosphere of 5% CO2.
MP isolation and identification
MPs were isolated from confluent VLB100, E1000, DX and
MCF-7/P-gp/EGFP cells by differential centrifugation, as previ-
ously described [2,23]. The MPs were designated VLBMP,
E1000MP, DXMP and GFP-MP respectively, for simplicity.
Briefly, culture supernatants (cell conditioned media) were
collected and centrifuged at 500 g for 5 min to pellet whole cells
and debris. The collected supernatant was re-centrifuged at
15,000 g for 1 h at 15uC to pellet the MPs. The final pellet was
resuspended in serum free RPMI 1640 media and centrifuged at
2000 g for 1 min to remove debris. The clear MP suspension was
further centrifuged at 18,000 g for 30 min at 15uC to pellet MPs.
Validation of the isolated MP pellet was performed using flow
cytometer (FCM) (BDTM LSR II, BD Biosciences) after FITC-
annexin V (Beckman Coulter, NSW, Australia) staining as
previously described [2]. Total protein content of MPs was
determined using the Quant-iTTM protein assay as per the
manufacturer’s instructions (Life Technologies).
MP transfer experiment
In a 96-well U bottom culture plates, 180 mg of VLBMP,
E1000MP or DXMP were co-cultured with 1610
5 MBE, HO-f or
HUC cells, for 4 h in a total of 200 mL complete culture medium
at 37uC and 5% CO2. Unbound MPs were removed by
centrifuging at 500 g for 5 min at 25uC after 4 h.
SDS-PAGE and Western Blotting
Total cellular proteins were separated on 4–12% NuPAGE Bis-
Tris gel (Life Technologies) before transferring to PVDF
membrane (Pall Australia, VIC, Australia). The membrane was
blocked, incubated with anti-P-glycoprotein mAb (clone F4), anti-
MRP1 mAb (clone QCRL-1) (Sigma-Aldrich, NSW, Australia),
anti-Ezrin mAb (clone 3C12) or anti-CD44 mAb (clone
EPR1013Y) (Abcam, MA, USA). Anti-a-tubulin (clone DM1A)
or anti-b-actin (clone AC-74) (Sigma-Aldrich) were used as the
internal controls, followed by horseradish peroxidase-conjugated
secondary antibody and subjected to enhanced chemilumines-
cence (Roche, VIC, Australia).
Confocal microscopy
Confocal microscopic experiments were performed on co-
cultures to complement the Western blot studies. Microparticles
(GFP-MPs) were isolated from MCF-7/P-gp/EGFP breast cancer
cells. Malignant drug sensitive MCF-7 cells or the non-malignant
osteoblasts (HO-f cells) were co-cultured with equal amounts of the
GFP-MPs for 4 hours on coverslips. Following co-culture,
unbound MPs were removed by rinsing twice with PBS for
10 mins. The cells were fixed with 2% paraformaldehyde (Sigma-
Aldrich) in PBS for 30 mins followed by two rinses with PBS. The
fixation was quenched with 100 mM glycine (Research Organics
Inc. OH, USA) for 5 mins. The cells were labelled with 200 nM of
the cell membrane dye PKH26 (Sigma-Aldrich) for 1 min
according to the manufacturer’s recommendation followed by
two rinses with PBS. The nucleus was stained with 300 nM DAPI
(Sigma-Aldrich) for 5 mins. Following two rinses with PBS, the
coverslips were mounted on slides with Prolong Gold Antifade
Reagent (Life Technologies). Images were acquired utilising
confocal laser scanning microscopy on a Nikon A1 microscope
(Nikon, Tokyo, Japan).
Flow cytometry
For the detection of cell surface CD44 in the breast cancer cells,
MCF-7 and DX cells were harvested either by scraping gently
from the tissue culture flask using a cell scraper or by trypsinising.
The leukaemic cells were harvested by centrifuging the cell
suspension at 500 g for 5 mins to obtain the cell pellet. 56105 cells
were labelled with 30 mL anti-CD44 (1:30) (mAb, clone
EPR1013Y) and incubated for 30 mins at room temperature in
the dark. Samples were washed three times in ice cold DPBS
(Sigma-Aldrich) by centrifuging at 500 g for 5 min at 25uC
followed by incubation with Alexa Fluor 647-conjugated goat anti-
rabbit IgG (Life Technologies) (1:400 dilution) for 30 mins at 4uC.
The cells were washed three times in DPBS as described above
and resuspended in 200 mL ice cold 3% BSA in DPBS and
analysed by flow cytometry (BDTM LSR II, BD Biosciences).
Binding of MPs to Non-malignant cells
The extent of fluorescence transfer of PKH26 labelled DXMPs
to non-malignant cells following co-culture was performed as
previously described [2]. Briefly, after MP purification, DXMPs
were labelled with PKH26 red dye (Sigma-Aldrich) according to
the manufacturer’s recommendation and designated PKH26-
DXMP. 16105 non-malignant breast epithelial cells and osteo-
blasts were co-cultured with PKH26-DXMP for 4 h at 37uC in
complete RPMI-1640 media. Cells were washed with DPBS and
centrifuged at 500 g for 5 min to remove unbound MPs. The cells
were re-suspended in 200 ml DPBS and analysed using flow
cytometry (BDTM LSR II, BD Biosciences).
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In vivo experiments
The use of animals in this study was approved by the UTS
Animal Care and Ethics Committee (ACEC) at the University of
Technology, Sydney (Permit No: 2011-321A) and the experiments
were conducted in accordance with the UTS (ACEC) approved
protocol. 30 BALB/c athymic nude female mice (4–6 weeks old),
weighing 15–20 g were obtained from the Animal Resources
Centre (WA, Australia). The animals were kept in groups of five
under sterile conditions in filter top cages and were provided with
sterilized food and water ad libitum throughout the experiment.
The mice were allowed to acclimatize in standard conditions
(under a 12 hr light/dark cycle) for 8 days prior to any
experimental procedures.
(i) Tumour induction. MCF-7 and DX tumour xenografts
were established as described by Ullmann and colleagues, 1991
[32]. The DX xenograft model has been validated as remaining
resistant and retaining the characteristics of MDR as displayed by
the cells in culture [32]. The MCF-7 and DX cells require
oestrogen for tumour growth in vivo [33] and hence, a 90-day slow
release 17-b-estradiol pellets (1.7 mg/pellet) (Innovative Research
of America, FL, USA) were implanted subcutaneously (s.c.) into
the dorsum of each mice under general anaesthesia (2% isoflurane
and 0.5–1% oxygen) one week prior to tumour cell injection.
Transplantable MCF-7 or DX cells were harvested and suspended
in RPMI supplemented with 10% FCS. All mice received s.c.
injections of 107 cells/100 mL of inoculation in between the
shoulder blades.
When the s.c. tumour reached a palpable size after ,10 days,
the mice were randomised into 2 groups (15 mice each) including
MCF-7 tumour bearing mice (10) and DX tumour bearing mice
(5) in each group. MPs were isolated from in vitro cultures of the
DX cells and designated as DXMP. Five MCF-7 tumour bearing
mice from each group received injections of 100 mg MP/200 mL
of RPMI supplemented with 10% FCS subcutaneously surround-
ing the tumour periphery. All the other mice (MCF-7 and DX
tumour bearing mice) from both groups served as controls and
received 200 mL of saline injections. The animals’ weight and
tumour volume was measured routinely during the course of the
experiment. Tumour volume (V) was measured in two perpen-
dicular diameters (A and B) using digital callipers (Dick Smith,
NSW, Australia) and calculated based on the formula: V= p/6
(A+B/2)3.
The animals were further divided into 2 groups; fifteen animals
for 24 h and fifteen for 14 days post injection monitoring.
Following 24 h post injection, all the mice in the respective group
were euthanized by CO2 inhalation. Tumours, lungs, livers and
kidneys were excised and preserved in 10% neutral buffered
formalin solution (Sigma-Aldrich) and embedded in paraffin. Both
haematoxylin and eosin (H&E) staining and immunohistochemical
detection were performed on tissue sections.
(ii) Immunohistochemistry. DakoCytomation EnVisionH +
Dual Link System-HRP (DAB+) kit (Dako, VIC, Australia) was
used for immunohistochemistry staining. 5 mm sections from
formalin-fixed and paraffin-embedded tissues were deparaffinised,
rehydrated and treated for 20 mins at 95uC in citrate antigen
retrieval buffer (pH 6.0) in a water bath. After cooling to room
temperature, slides were blocked with the Dual Endogenous
Enzyme block (from Dako kit) for 10 mins. The slides were rinsed
with distilled water and kept in PBS-T (0.05% Tween 20 in PBS)
for 5 mins. Sections were incubated overnight at 4uC with mouse
monoclonal anti-P-glycoprotein (1:100) clone F4 (Sigma-Aldrich)
or mouse isotype IgG1 (1:100) (Cell Signaling, MA, USA) diluted
in 1% bovine serum albumin (Sigma-Aldrich). Sections were
washed in PBS-T three times for 5 mins each and subsequently
incubated with labelled Polymer-HRP (from Dako kit) for 1 h at
room temperature. Following four washes with PBS, substrate-
chromogen solution (DAB+) was applied for 15 mins. The sections
were counterstained with filtered Harris’s haematoxylin (Thermo
Fisher Scientific, NSW, Australia) for 30 sec, dehydrated by
washing in a series of ethanol at increasing concentrations, and
mounted with a coverslip with EukittH quick-hardening mounting
medium (Sigma-Aldrich). The sections were visualized with the
Olympus BX51 microscope and images captured using the
Olympus DP 70 (Olympus, Japan) camera.
Statistical analysis
GraphPad Prism software was used to plot the data and a one-
way analysis of variance (ANOVA) was used for comparison and
statistical analysis between the sample populations. P values less
than 0.05 (p,0.05) were accepted as statistically significant.
For the animal experiments, the study was carried out on 30
mice with equal numbers in each of the 3 treatment groups in
order to be statistically significant. The comparison of groups was
based on in vitro P-gp expression experiments using the sample size
calculator of the Minitab software version 15.1. The power, with a
two-sided significance level of 5%, to detect our smallest observed
increase in P-gp expression following MP transfer in our in vitro
pilot data (13%) with 10 mice per group was .80%.
Results
Breast Cancer-derived MPs Selectively Transfer P-gp to
Malignant Breast Cells
To establish whether the drug resistant cancer-derived MPs
transferred the drug transporter proteins to the non-malignant
cells, we conducted a Western blot analysis probing for acquisition
of the transporters, P-gp and MRP1. P-gp was identified at
170 kDa and MRP1 at 190 kDa. P-gp was overexpressed in both
the leukaemic and breast cancer resistant cells as well as in their
shed MPs (Figure 1A and C). Likewise MRP1 was overexpressed
in the leukaemic resistant cell and its shed MPs (Figure 1B). Both
P-gp and MRP1 were also detected in all the drug sensitive cancer
cells following MP co-culture with MPs isolated from drug
resistant cells (Figure 1), consistent with our previous findings
[2,23]. Likewise P-gp expression was detected in all non-malignant
cells following co-culture with resistant leukaemic cell-derived MPs
(VLBMP) (Figure 1A). Similarly, MRP1 was detected in all non-
malignant cells following resistant leukaemic cell-derived MP
(E1000MP) co-culture (Figure 1B). Interestingly, P-gp was not
detected in any non-malignant cells, following co-culture with
DXMPs (Figure 1C). Rather, we observed a selective transfer of P-
gp by resistant breast cancer-derived DXMPs to malignant breast,
MCF-7 cells only (Figure 1C).
In addition, consistent with the Western blot studies, we showed
by confocal microscopy that the malignant breast cancer-derived
GFP-MPs bind and transfer P-gp to malignant MCF-7 cells only
(Figure 1D: IA) and not to the non-malignant osteoblasts
(Figure 1D: IIA).
Transfer Selectivity is Not a Result of Limitations in MP
Binding to Recipient Cells
To establish whether the lack of DXMP transfer of P-gp to non-
malignant cells was the result of limitations in MP binding to the
recipient cells, PKH26-labelled DXMP were incubated with either
the human breast epithelial cells (MBE) or the human osteoblasts
(HO-f). Following a 4 h co-incubation, flow cytometric analysis of
the resultant recipient breast epithelial cells displayed a 96%
(Figure 2A) and the osteoblasts a 48% (Figure 2B) increase in
Microparticles Display Tissue Selectivity
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Figure 1. Selective transfer of P-gp to MCF-7 breast cancer cells by DXMPs by Western Blot analysis. 20 mg total cell lysates of non-
malignant cells (breast epithelial cells (MBE), osteoblasts (HO-f) and urothelial (HUC) cells) and their co-cultures; and drug sensitive cancer cells
(leukaemia, CEM and breast cancer, MCF-7) and their co-cultures with leukaemic cell-derived (A) VLBMP and (B) E1000MP overexpressing P-gp and
MRP1, respectively, and breast cancer-derived (C) DXMP overexpressing P-gp, were analyzed by Western blot analysis. (A) P-gp and (B) MRP1 were
readily detected in the drug resistant leukaemic donor cells, their MPs and also in both the recipient malignant and non-malignant cells after MP
transfer using the anti-P-gp mAb, F4 and anti-MRP1 mAb, QCRL-1, respectively. (C) P-gp was also detected in the drug resistant breast cancer donor
cell, its MPs (DXMP), recipient malignant drug sensitive cells but not in the recipient non-malignant cells after MP transfer. a-tubulin or b-actin were
used as internal loading controls. (D) Selective transfer of P-gp to MCF-7 breast cancer cells by malignant breast cancer-derived MPs by
Confocal microscopy. Malignant breast cells MCF-7 (I) or non-malignant osteoblasts, HO-f (II) cells were stained with fluorescent membrane
probes PKH26 and the nucleus was stained with DAPI after 4 hours co-culture with GFP-MPs. (I) P-gp was detected in the breast MCF-7 cells only and
not in (II) the osteoblasts. Panel A shows all channels captured, Panel B shows the DAPI in the 405 nm channel, Panel C shows the transferred GFP (or
lack of) in the 488 nm channel, and Panel D shows the PKH26 in the 561 nm channel. Images were acquired using the Nikon A1 confocal microscope.
Scale bar as indicated. Both Western blot and confocal microscopy experiments were repeated at least 2–3 times with similar results. Data are
representative of a typical experiment.
doi:10.1371/journal.pone.0061515.g001
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Figure 3. Breast cancer-derived MPs transfer Ezrin to recipient cells. 17.5 mg total cell lysates of breast epithelial cells, osteoblasts and
urothelial cells and their co-cultures with (A) leukaemic cell-derived MPs namely VLBMP and (B) Breast cancer-derived MPs namely DXMP both
overexpressing P-gp were analyzed by Western blot analysis followed by densitometric quantification after normalization to total protein loaded to
the gel. (A) The presence of Ezrin in the leukaemic cell-derived VLBMP and in the recipient cells after MP transfer was readily detected using the anti-
Ezrin mAb, 3C12. (B) Ezrin was also detected in the breast cancer DXMP and in all the recipient cells after MP transfer. b-actin was used as an internal
loading control. The Western blot experiments were repeated at least three times with similar results. Data are representative of a typical experiment.
Densitometric data represent the mean 6 SEM of 3 independent experiments * p,0.05.
doi:10.1371/journal.pone.0061515.g003
Figure 2. Detection of PKH-26 labeled DxMP binding to normal cells by flow cytometry (FCM). After purification and staining, the co-
incubation of PKH-26 DXMP labelled DXMPs (A) 96% of the breast epithelial (MBE) cells (black histogram) and (B) 48% of the osteoblasts (HO-f)
showed PKH26 fluorescence (black histogram) with respect to the cells with no MP incubation (gray histograms). The experiment was repeated at
least 2–3 times with similar results. Data are representative of a typical experiment.
doi:10.1371/journal.pone.0061515.g002
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PKH26 labelling compared to the cells alone, consistent with the
binding of PKH26-DXMP to the surface of these cells.
Ezrin is Selectively Packaged in Cancer-derived MPs
Since Ezrin plays a role in P-gp membrane insertion through a
cytoskeletal association [34], we sought to examine whether Ezrin
levels correlated with the transfer selectivity observed. Ezrin was
present in both leukaemic and breast cancer-derived MPs, where it
was selectively packaged relative to the donor cells (Figure 3). We
observed no significant differential expression of Ezrin in the
recipient cells beyond their endogenous levels present, before or
after co-culture (Figure 3) and hence transfer selectivity does not
appear related to differential levels of Ezrin.
The Cell Adhesion Molecule CD44 is Selectively Present
on Breast Cancer-derived MPs
Since CD44 has been previously shown to associate with P-gp
and the cytoskeleton, we sought to assess whether CD44 was
present in DXMP, whether it was differentially expressed with
respect to VLBMPs and as such could account for the observed
transfer selectivity. CD44 (isoform 10) was found to be selectively
packaged in the breast cancer-derived DXMP relative to its donor
cells, where surprisingly no CD44 was detected by Western blot
(Figure 4A). However, CD44 was detected in the donor DX cells
by flow cytometry, where 75% of the cell population harvested
without trypsinising stained positive for CD44 whereas only 46%
stained positive for CD44 following cell harvest using trypsin
(Figure 4C [a–d]). In contrast, insignificant levels (3–3.5%) of
CD44 was detected in the leukaemic cells (Figure 4C [e–f]).
Figure 4. Breast cancer MPs carry but do not transfer CD44 to recipient cells. 20 mg total cell lysates of (A) drug sensitive cancer cells
(leukaemia, CEM and breast cancer, MCF-7) and their co-cultures; (C) non-malignant cells (breast epithelial cells (MBE), osteoblasts (HO-f) and
urothelial (HUC) cells) and their co-cultures; with leukaemic cell-derived VLBMP and breast cancer-derived DXMP both overexpressing P-gp were
analyzed by Western blot analysis. (A) CD44 was only detected in the breast cancer DXMP but not in the malignant MCF-7 cell (A), or in any of the
non-malignant cells (B) following DXMP co-culture. (A) CD44 was not detected in the leukaemic cell-derived VLBMP, the malignant cells or (B) the
non-malignant cells follwoing VLBMP co-culture using the anti-CD44 mAb, clone EPR1013Y. b-actin or a-tubulin or were used as an internal loading
control. The Western Blot experiments were repeated at least three times with similar results. (C) Detection of CD44 on breast cancer and
leukaemic cells by flow cytometry. MCF-7 (a–b) and DX (c–d) cells were harvested from culture flasks either by scraping (a and c) or by
trypsinising (b and d). Leukaemic CEM (e) and VLB100 (f) cells were harvested by centrifuging the cell suspension. Cells were surface labelled with anti-
CD44 (1:30) (mAb, clone EPR1013Y) followed by Alexa Fluor 647-conjugated goat anti-rabbit IgG (1:400). No CD44 was detected on the MCF-7 cells
harvested without (a) or with trypsin (b). 75% DX cells harvested without (c) or 46% DX cells harvested with trypsin (d), were detected positive for
CD44 with respect to the secondary control by flow cytomtery. Almost equal percentage (3.1–3.5%) of CEM (e) and VLB100 (f) cells were detected
positive for CD44 with respect to the secondary control. Data are representative of a typical experiment.
doi:10.1371/journal.pone.0061515.g004
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Likewise, CD44 was not present in the leukaemic cell-derived
VLBMP (Figure 4A) or any of the malignant (Figure 4A) or non-
malignant cells (Figure 4B) following both DXMP and VLBMP
co-cultures (Figure 4). This result demonstrates that CD44
(isoform 10) is selectively present in DXMPs however it is not
transferred to recipient cells.
MP Transfer of P-gp to Breast Cancer Cells Localizes to
the Tumour Core and is Stable for at Least Two Weeks In
Vivo
To ascertain MP-mediated acquisition of P-gp in the in vivo
state, we examined P-gp transfer by DXMPs using the MCF-7
tumour xenograft model. Female athymic nude mice were used for
the drug sensitive (MCF-7) and the drug resistant (DX) tumour
xenografts. Breast epithelial cells were confirmed in all tumour
samples by histopathological examination (Figure 5A). P-gp was
acquired following a single subcutaneous injection of DXMPs
surrounding the tumour periphery. P-gp localized to the tumour
core of recipient breast MCF-7 tumours at both 24 h and 14 days
post MP exposure (Figure 5B). P-gp expression was stable for at
least 2 weeks following a single dose of DXMPs (Figure 5B) in the
absence MP re-administration or any selective pressure.
DXMP transfer of P-gp was not observed at the level of kidney
(Figure 5C) or lung (data not shown).
Discussion
In this study we show that MPs display "tissue selectivity" in
transferring cancer traits to recipient cells. Specifically, MPs shed
by multidrug resistant DX breast cancer cells, selectively transfer
resistance proteins to malignant MCF-7 breast cells (Figure 1C,
1D: I). Contrary to this however, leukaemic cell-derived MPs
(VLBMPs), effectively transfer P-gp (Figure 1A) and MRP1
(Figure 1B) to non-malignant and malignant recipient cells. The
observed selectivity was not the result of limitations in MP binding
to recipient cells (Figure 2). Nor was it the result of limitations of
recipient cell plasma membranes for intercellular exchange, given
the non-selective crosstalk observed by the leukaemic cell-derived
MPs. The basis of the observed transfer selectivity thus appears not
to reside at the recipient cell membrane but rather at the level of
MPs. As P-gp resides both inside and outside membrane rafts,
membrane ultrastructures at the level of the MPs appears unlikely
to govern the observed transfer selectivity [35]. On this basis we
further propose that the specificity displayed by the cancer derived
DXMPs likely resides at the protein level.
Ezrin, through cytoskeletal association, is known to play a role
in P-gp membrane localization. The actin-P-gp interaction was
also shown to be required for the endosomal trafficking of P-gp to
the plasma membrane [29,34]. Disruption of the ERM–P-gp
association impairs P-gp function and results in a cellular
redistribution of P-gp [34], supporting an essential role for the
ERM proteins in the plasma membrane localization of P-gp.
Given the role of Ezrin in P-gp membrane insertion, we examined
whether Ezrin levels correlated with transfer selectivity. Ezrin was
shown to be selectively packaged in both leukaemic and breast
cancer-derived MPs relative to their donor cells (Figure 3).
However, we observed no difference in levels across both
malignant and non-malignant cells pre and post MP exposure.
Our results, establish that the transfer selectivity observed by
DXMPs does not directly reside at the level of Ezrin expression
but may reside with other cytoskeletal associated proteins or their
effectors.
Figure 5. P-gp localised and retained in tumour core, two weeks post MP administration. At 10 days after tumour cell implantation,
tumours derived from female athymic mice bearing MCF-7 (negative control) and DX (positive control) or MCF-7 tumours with DXMP exposure (MCF-
7+DXMP) were resected and fixed after 24 h and 14 days DXMP exposure. Five independent tumours (each from a different mouse) were tested in
each mouse group. (A) Excised and sectioned tumour slides were subjected to haematoxylin and eosin (H&E) staining showing the presence of breast
epithelial cells and blood vessels in the tumour sections at both 24 h and 14 days. Slides were examined at 406 followed by 1006magnification. (B)
Tumour and (C) kidney specimens were subjected to immunohistochemical (IHC) staining with antibodies specific to P-glycoprotein (anti-P-gp mAb,
F4) and its Ig G isotype control. (B) P-gp (indicated in black arrows) was found in MCF-7 tumours, 2 weeks post DXMP exposure. P-gp was observed in
MCF-7 tumours (-ve control) and DX tumours (+ve control). (C) No P-gp was observed in kidney 14 days after DXMP administration. Slides were
examined at 106 or 206magnification. Images are of a representative animal.
doi:10.1371/journal.pone.0061515.g005
Figure 6. Hypothesis Overview. An interaction complex involving discrete MP surface molecules and FERM domain proteins (including Ezrin)
serve to selectively target and anchor P-gp to breast cancer cells upon MP binding. This leads to the selectivity in dissemination and acquisition of
MDR trait in cells.
doi:10.1371/journal.pone.0061515.g006
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Another cell adhesion molecule, CD44, which interacts with P-
gp via FERM domain binding proteins, was also assessed in
understanding the basis of the transfer selectivity observed for
breast cancer-derived DXMPs. We observed that CD44 (isoform
10) was selectively packaged by the DXMPs relative to the donor
cells where its presence was undetected by Western blot
(Figure 4A). When assessed by flow cytometry however, the donor
DX cells were positive for CD44 (Figure 4C, c–d). This implies
that the CD44 protein in the donor cells may be prone to
degradation and/or have altered conformation due to trypsin
treatment and/or lysis. Hence, the cell surface CD44 protein is
only detected by flow cytometric analysis on the live cells without
lysis or trypsinisation (Figure 4C [a–d]). In contrast, we failed to
detect significant levels of the CD44 isoform 10 in the leukaemic
cells (not treated by trypsin) by flow cytometry (Figure 4C [e–f]).
Likewise, no CD44 was detected in the drug resistant cell-derived
VLBMP and in any of the recipient cells following both DXMP
and VLBMP co-cultures (Figure 4B) by Western blot. This
observation, in addition to CD44’s exclusivity of presence in the
breast cancer-derived MPs is indeed surprising and requires
further examination. These results also demonstrate that although
CD44 is present in DXMPs, it is not transferred. Rather, its
presence in MPs may be required to stabilise P-gp within the MP
membrane whilst en route to recipient cells and may have an
important role at the MP level for the selective transfer of P-gp to
malignant breast cells whilst it is not transferred itself. Given the
cytoskeleton plays an important role in MP biogenesis and the
membrane localisation of P-gp via the FERM domain proteins, we
hypothesise that an interaction complex involving discrete MP
surface molecules and FERM domain proteins (like Ezrin) may
serve to selectively target and anchor P-gp to breast cancer cells
upon MP binding (Figure 6).
In addition to cell adhesion molecules, there are a diversity of
other molecules such as cellular proteins, growth factors, second
messengers and other nucleic acids species (RNA and miRNAs)
that have been implicated in intercellular communication via
membrane vesicles [3,18]. Indeed we have shown the transfer of
not only functional P-gp [2] but also RNAs and miRNAs [18,23]
via MPs leading to the re-templating of the recipient cells to ensure
acquisition of the donor cell MDR trait [18,23]. In addition to the
involvement of these entities in the transfer selectivity observed by
breast cancer-derived MPs, it may be worth examining the role of
other mechanisms of intercellular communication in the transfer
selectivity as well as dissemination selectivity of MDR traits in
cancer.
Finally, the transfer of P-gp by DXMPs in the in vivo state was
examined using a breast cancer (MCF-7) tumour xenograft model
in athymic nude mice. Remarkably we observed that P-gp was
acquired following a single subcutaneous injection of DXMP
surrounding the tumour mass and was localized to the tumour
core of the recipient breast MCF-7 tumours (Figure 5B) within
24 hours of MP administration. P-gp expression was stable for at
least 2 weeks following a single dose of DXMPs (Figure 5B), in the
absence of any selective pressure such as drugs or MP re-exposure.
DXMP transfer of P-gp was not observed in the non-malignant
organs such as kidney (Figure 5C) and the lung (data not shown).
Endogenous P-gp was detected in the liver, however the levels
were no different from untreated controls (data not shown). The
absence of P-gp detection in these organs could possibly be
attributed to the subcutaneous injection of MPs, which were not
injected in the immediate vicinity of these organs. Hence, future
studies will involve examining the effects on other organs,
following intravenous administration of MPs. Our results validate
for the first time the significance of MP mediated transfer of P-gp
in vivo and more importantly demonstrate a prolonged retention of
transferred P-gp following a single dose, even in the absence of a
selective pressure. It is currently unknown whether for a tumour to
develop the MDR phenotype, it is necessary only for a few cells to
acquire the phenotype or the majority of the cells in the tumour to
develop the resistance independently. It will also be interesting to
explore in future whether a single cell has the potential to pass
onto the acquired trait to its neighbouring cells or to its daughter
cells.
In conclusion, we demonstrate for the first time the acquisition
and the stability of MDR mediated by MPs in cancer cells in vivo.
The stable resistance acquired by MP-mediated P-gp transfer in
vivo has the potential to provide the drug sensitive cells a quick
survival advantage and a barrier to xenobiotic exposure, making
cancer treatment even more challenging. In addition, we also
report that MP-mediated transfer of P-gp is a "tissue selective"
process dependent on the donor MP type.
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